Companies › Haisco Pharmaceutical Group
18 active drug programs in 33 registered trials: 17 Phase 1, 9 Phase 2, 5 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cipepofol (HSK3486) GABA-A receptor; anion channel agonist | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Anesthesia; Myocardial Injury | – |
| HSK31858 | – | Phase 3 | Non-cystic Fibrosis Bronchiectasis; Healthy Subjects; Non-cystic Fibrosis Bronchiectasis (NCFBE) | Nov 2026 |
| HSK39297 complement C5 inhibitor | – | Phase 3 | IgA Nephropathy (IgAN); Paroxysmal Nocturnal Hemoglobinuria; Lupus Nephritis (LN); Paroxysmal Nocturnal Hemoglobinuria (PNH) | Dec 2026 |
| HSK39004 inhalation suspension | – | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease); COPD Patients | Sep 2027 |
| HSK31679 | – | Phase 3 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Jun 2029 |
| HSK55718 | – | Phase 2 | Pain After Surgery | Nov 2026 |
| HSK47388 | – | Phase 2 | Ulcerative Colitis (UC) | Oct 2027 |
| HSK39004 Dry Powder Inhaler | – | Phase 2 | Chronic Obstructive Lung Disease (COLD); Chronic Obstructive Pulmonary Disease (COPD) | – |
| HSK46575 | – | Phase 1 | m CRPC | Dec 2026 |
| HSK56630 | – | Phase 1 | Healthy Volunteer | Dec 2026 |
| HSK44459 Cream | – | Phase 1 | Psoriasis | Mar 2027 |
| HSK40118 EGFR inhibitor | EGFR | Phase 1 | NSCLC | Jun 2027 |
| HSK42360 BRAF V600 inhibitor | BRAF | Phase 1 | Solid Tumors; Malignant Brain Tumors | Jul 2027 |
| HSK47977 BTK inhibitor | – | Phase 1 | NHL | Dec 2027 |
| HSK41959 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumors | May 2028 |
| HSK42360-Na BRAF V600 inhibitor | BRAF | Phase 1 | Solid Tumors (Phase 1); Metastatic Colorectal Cancer (CRC) | Dec 2028 |
| HSK46256 PARP1 inhibitor | PARP1 | Phase 1 | Advanced Solid Tumor (Phase 1) | Dec 2028 |
| HSK55879 | – | Phase 1 | Healhty | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07134478 | HSK31858 | Phase 1 | Healthy Subjects | Other | Dec 2024 |
| NCT06740201 | Cipepofol (HSK3486) | Phase 4 | Anesthesia | Other | Mar 2025 |
| NCT07140328 | HSK39004 Dry Powder Inhaler | Phase 2 | Chronic Obstructive Lung Disease (COLD) | Respiratory | Jul 2025 |
| NCT07140328 | HSK39004 Dry Powder Inhaler | Phase 2 | Chronic Obstructive Lung Disease (COLD) | Respiratory | Jul 2025 |
| NCT07152288 | HSK39297 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hematology | Sep 2025 |
| NCT07331402 | HSK39004 inhalation suspension | Phase 2 | COPD Patients | Respiratory | Dec 2025 |
| NCT07521345 | HSK55879 | Phase 1 | Healhty | Other | Jun 2026 |
| NCT07108699 | HSK39004 Dry Powder Inhaler | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Aug 2026 |
| NCT07915011 | HSK31858 | Phase 1 | Non-cystic Fibrosis Bronchiectasis (NCFBE) | Respiratory | Nov 2026 |
| NCT07915024 | HSK31858 | Phase 1 | Non-cystic Fibrosis Bronchiectasis (NCFBE) | Respiratory | Nov 2026 |
| NCT07533786 | HSK55718 | Phase 2 | Pain After Surgery | Other | Nov 2026 |
| NCT06660992 | HSK31858 | Phase 3 | Non-cystic Fibrosis Bronchiectasis | Respiratory | Nov 2026 |
| NCT07616700 | HSK39297 | Phase 2 | IgA Nephropathy (IgAN) | Genitourinary | Dec 2026 |
| NCT07913009 | HSK31858 | Phase 1 | Non-cystic Fibrosis Bronchiectasis (NCFBE) | Respiratory | Dec 2026 |
| NCT07007910 | HSK46575 | Phase 1 | m CRPC | Oncology | Dec 2026 |
| NCT07580794 | HSK56630 | Phase 1 | Healthy Volunteer | Other | Dec 2026 |
| NCT07623486 | HSK44459 Cream | Phase 1 | Psoriasis | Immunology | Mar 2027 |
| NCT06050980 | HSK40118 | Phase 1 | NSCLC | Oncology | Jun 2027 |
| NCT06745622 | HSK39297 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Jun 2027 |
| NCT06536400 | HSK42360 | Phase 1 | Solid Tumors | Oncology | Jul 2027 |
| NCT07583849 | HSK39004 inhalation suspension | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Sep 2027 |
| NCT07028593 | Cipepofol (HSK3486) | Phase 4 | Myocardial Injury | Oncology | Oct 2027 |
| NCT07335055 | HSK47388 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Oct 2027 |
| NCT07363460 | HSK39297 | Phase 2 | Lupus Nephritis (LN) | Immunology | Nov 2027 |
| NCT07390123 | HSK39297 | Phase 3 | IgA Nephropathy (IgAN) | Genitourinary | Dec 2027 |
| NCT07283796 | HSK47977 | Phase 1 | NHL | Oncology | Dec 2027 |
| NCT06968572 | HSK41959 | Phase 1 | Advanced Solid Tumors | Oncology | May 2028 |
| NCT07561554 | HSK42360-Na | Phase 1 | Solid Tumors (Phase 1) | Oncology | Dec 2028 |
| NCT07695142 | HSK46256 | Phase 1 | Advanced Solid Tumor (Phase 1) | Oncology | Dec 2028 |
| NCT07616375 | HSK31858 | Phase 3 | Non-cystic Fibrosis Bronchiectasis | Respiratory | Jan 2029 |
| NCT07158710 | HSK42360 | Phase 1 | Malignant Brain Tumors | Oncology | May 2029 |
| NCT07581951 | HSK31679 | Phase 3 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Gastroenterology | Jun 2029 |
| NCT07790510 | HSK42360-Na | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oncology | Sep 2029 |
Jiangsu Hansoh Pharmaceutical Ono Pharmaceutical Sunshine Lake Pharma Beijing InnoCare Pharma Tech Abbisko Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.